ADC Drug Substance Manufacturing

Antibody-drug conjugate (ADC) drug substance manufacturing requires precise control of antibody–linker–payload conjugation, purification, and product quality to consistently produce ADC materials with defined molecular characteristics. Manufacturing processes must be carefully controlled to maintain attributes such as drug-to-antibody ratio (DAR), purity, molecular integrity, and product consistency.

Protheragen provides ADC Drug Substance Manufacturing services to support the transition from process development to manufacturing, including ADC conjugation, purification, drug substance processing, and manufacturing-stage analytical support. Manufacturing solutions can be adapted to different development stages and project requirements, supporting ADC programs from preclinical material preparation through clinical development and later-stage manufacturing.

Overview of ADC Drug Substance Manufacturing

ADC drug substance manufacturing integrates bioconjugation and downstream processing to convert an antibody and linker-payload components into a purified ADC drug substance with controlled quality attributes. Compared with conventional biologics manufacturing, ADC production requires additional control of conjugation-related characteristics, including DAR, drug distribution, unconjugated species, free payload, and molecular heterogeneity.

A manufacturing strategy typically connects process transfer, conjugation, purification, concentration or buffer exchange, in-process monitoring, and final drug substance handling. Appropriate analytical controls are incorporated throughout the process to monitor critical quality attributes and support consistent production from development-stage material to clinical and commercial supply.

Our Services

ADC drug substance manufacturing integrates controlled conjugation, purification, and drug substance processing to produce ADC materials with consistent molecular and quality attributes. Depending on the development stage and manufacturing objectives, individual activities can be configured to support process transfer, scale-up, clinical supply, and later-stage manufacturing.

ADC Drug Substance Quality Attributes

ADC drug substance manufacturing is closely connected with analytical characterization and quality control. Relevant quality attributes can include:

The exact analytical panel should be determined according to the ADC molecule, conjugation strategy, development stage, and manufacturing objectives.

Integrated ADC Drug Substance Manufacturing Workflow

ADC drug substance manufacturing integrates process transfer, controlled conjugation, purification, and quality assessment into a coordinated manufacturing workflow. Each stage is supported by appropriate process controls and analytical monitoring to help maintain consistent product quality and facilitate the transition from development-stage material to clinical and later-stage supply.

Integrated Manufacturing & Analytical Support

ADC drug substance manufacturing is closely connected with the analytical services described in the ADC Analytical Support section.

• Process & Analytical Development

Analytical data generated during process development can help define manufacturing controls and monitor critical quality attributes during production.

• Structure & Quality Characterization

Structural characterization provides information on identity, DAR, drug distribution, molecular integrity, aggregation, charge heterogeneity, and other attributes relevant to manufacturing consistency.

• Stability & Comparability Studies

Stability and comparability studies can evaluate whether drug substance quality remains consistent during storage or following manufacturing, process, formulation, scale-up, or site changes.

Why Choose Protheragen

• Integrated ADC Manufacturing Support

Protheragen connects ADC drug substance manufacturing with process development, analytical characterization, quality assessment, and downstream drug product manufacturing.

• Controlled Conjugation & Purification

Manufacturing processes are designed around controlled conjugation and downstream purification to support consistent product quality and molecular characteristics.

• Development-to-Manufacturing Continuity

Process knowledge and analytical information generated during development can be carried into manufacturing to support a more continuous development pathway.

• Flexible Stage-Specific Support

Manufacturing strategies can be adapted to preclinical, IND-enabling, clinical, late-stage, and commercial preparation requirements.

• Analytical-Driven Manufacturing

Manufacturing-stage analytical testing can be used to monitor relevant ADC quality attributes and support process understanding and consistency.

• Support for Scale-Up & Technology Transfer

Process transfer, scale-up evaluation, analytical alignment, and manufacturing readiness activities can help bridge development and manufacturing.

ADC drug substance manufacturing requires coordinated control of conjugation, purification, and product quality to produce ADC materials with consistent molecular and physicochemical characteristics. By integrating manufacturing execution with process knowledge, analytical characterization, and quality assessment, Protheragen supports ADC programs across different stages of development. From process transfer and conjugation through purification, drug substance processing, and manufacturing-stage quality assessment, Protheragen provides flexible ADC Drug Substance Manufacturing solutions designed to support clinical development and future manufacturing requirements. Contact us to discuss your ADC drug substance manufacturing requirements and develop a manufacturing strategy aligned with your molecule, process, and development stage.